Compounded Bi-Est Explained: What It Is, and Why It's Not a Patch Conversion
Bi-Est combines estriol and estradiol in one prescriber-set ratio, one of the most-prescribed compounded hormone formulas. Here's how it differs from estradiol-only therapy, and the conversion rule every patient should understand.
The short answer: Bi-Est is a compounded blend of two bioidentical estrogens, estriol and estradiol, classically in an 80/20 ratio, that exists only through compounding pharmacies and only by prescription. It is not an interchangeable substitute for estradiol-only therapy. If your estradiol patch is unavailable in the current shortage, the direct conversion is to compounded estradiol alone. Any move to Bi-Est is a separate, deliberate clinical decision by your prescriber.
KeyPoints
- Bi-Est = estriol (E3) + estradiol (E2) in a prescriber-set ratio, commonly 80/20
- No manufactured Bi-Est exists. It is compounding-only, by prescription
- Estradiol patches contain estradiol only; patch conversions go to estradiol-only preparations
- Switching to Bi-Est adds a hormone you weren't taking, never a default shortage swap
- All estrogen therapy requires prescriber oversight, monitoring, and usually progesterone if you have a uterus
EndKeyPoints
What exactly is in Bi-Est?
The body makes three main estrogens: estradiol (E2, the most potent), estriol (E3, the weakest), and estrone (E1). Commercial HRT products deliver estradiol. Bi-Est combines estriol and estradiol in one preparation. Most often a topical cream dosed in a metered dispenser, though troches and other forms exist. An "80/20 Bi-Est 2.5 mg" cream, for example, delivers 2.0 mg estriol and 0.5 mg estradiol per dose. Both the ratio and the total are your prescriber's levers: 80/20 and 50/50 are the common patterns, but any ratio can be compounded.
How does it differ from estradiol-only therapy?
| Factor | Estradiol-Only (Patch, Gel, Compounded E2) | Bi-Est (Compounded) |
|---|---|---|
| Estrogens delivered | Estradiol | Estriol + estradiol |
| Relative potency | Full-strength estrogen | Estradiol component + weaker estriol component |
| Commercial availability | FDA-approved products exist | Compounding only |
| Evidence base | Extensive trial data | Less extensive; prescriber-judgment territory |
| Typical rationale | Vasomotor symptoms, bone protection | Providers who want estriol's tissue support in the blend |
Neither is "the better hormone." Estradiol-only therapy has the deepest evidence and the regulatory approvals; Bi-Est offers a customization path some providers value. What matters is that they are different therapies. Which leads to the rule this post exists to make unmissable.
The conversion rule: patches convert to estradiol, full stop
We've published a full estradiol patch shortage conversion guide with dose-equivalence tables your provider can use, and a companion shortage explainer. If your provider reviews your case and chooses Bi-Est intentionally, some do, particularly when vaginal and skin symptoms are prominent, that's a legitimate path. It just shouldn't happen by accident at the pharmacy counter.
Who do providers actually prescribe Bi-Est for?
- Patients with prominent urogenital and skin symptoms: estriol's tissue-supportive profile is the usual rationale for including it
- Patients whose providers practice ratio-based BHRT: integrative and menopause-focused clinicians who titrate both the estradiol component and the blend
- Patients needing doses between commercial increments: the same precision argument that applies to all compounded BHRT
Patients with a uterus typically receive progesterone alongside any systemic estrogen for endometrial protection, another prescriber decision, and another formulation we compound.
What monitoring should you expect?
The same diligence as any hormone therapy. Baseline labs and history first. Follow-up estradiol levels and a symptom review roughly 4–6 weeks after starting or changing the dose. Then periodic reassessment of the risks and benefits with your provider. Hormone therapy is never "set and forget," compounded or otherwise.
Talk to your provider, then send us the script
Whether the destination is estradiol-only or Bi-Est, your prescriber can e-prescribe via SiPrescribe, fax, or call. Read the BHRT patient guide, browse hormone therapy options, or call 424-228-1049. Our pharmacists are happy to walk your provider through formulation choices.
Frequently Asked Questions
What is Bi-Est?
Bi-Est is a compounded combination of two bioidentical estrogens, estriol (E3) and estradiol (E2), most commonly in an 80/20 estriol-to-estradiol ratio, prepared as a topical cream or other prescriber-selected form. The ratio and total dose are set by your provider; no manufactured Bi-Est product exists, so it is compounding-only.
How is Bi-Est different from estradiol-only therapy?
Estradiol-only products (patches, gels, most commercial HRT) deliver a single estrogen, estradiol, the most potent of the body's estrogens. Bi-Est adds estriol, a weaker estrogen. They are different therapies with different clinical reasoning, not interchangeable versions of the same thing.
My estradiol patch is on backorder. Should I switch to Bi-Est?
Not as a default. A patch contains only estradiol, so the like-for-like conversion is to a compounded estradiol-only cream, gel, or troche at a dose your provider matches to your patch strength. Adding estriol, i.e., moving to Bi-Est, changes your therapy and is a separate clinical decision your prescriber must make deliberately.
Why do prescribers choose Bi-Est for some patients?
Some providers favor including estriol for its weaker systemic estrogenic activity and its role in supporting vaginal and skin tissue, while keeping an estradiol component for vasomotor symptom relief. Practice patterns vary, and the evidence base for estriol blends is less extensive than for estradiol alone. It is a prescriber-judgment therapy.
Does Bi-Est require monitoring?
Yes, like all hormone therapy. Expect baseline labs and history, follow-up labs after starting or changing dose, and ongoing reassessment. Progesterone is typically co-prescribed for uterine protection in patients with a uterus; that decision also belongs to your provider.
Disclaimer: This content is provided for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional regarding any medical condition or before starting any new treatment.
Related Articles
Compounded Peptides in 2026: What the FDA Panel Changed, and What a Non-Sterile Pharmacy Can Make Today
In July 2026 an FDA advisory committee recommended six peptides for the 503A list. None of them is legal to compound yet. Here is where each one stands, which peptides are components of approved drugs, and the non-peptide formulas prescribers are asking for most.
Compounded Testosterone: How Prescribing Works in California
Testosterone is a Schedule III controlled substance. Here is how a compounded testosterone prescription reaches a California pharmacy: who can write it, how it has to be sent, and why the pharmacy needs a DEA registration. Rx-only, prescriber-directed.
Understanding Hyperpigmentation and the Ingredients that Target it
Learn about the science behind hyperpigmentation and the ingredients prescribers use for different types of skin discoloration.